For the first time in over four decades, researchers are returning to examining the therapeutic benefits of mind altering substances, including MDMA (ecstasy), psilocybin (mushrooms), marijuana and LSD. In the 1970s the study of all psychedelics was criminalized in the US, despite emerging evidence of their medical value. Over the past decade, the Multidisciplinary Association for Psychedelic Research (MAPS) has helped to revive psychedelic research, sponsoring studies across the United States and around the world, including MDMA-assisted therapy for PTSD, and end-of-life anxiety. The results have been very positive, lasting over 72 months of follow-up, with few adverse effects. Psychedelics may promote a deepening and acceleration of the psychotherapeutic process. During therapy, people often are able to access and find peace with disavowed, "exiled" parts of themselves. In this recording, the Principal Investigator of the Phase I and II level trials will discuss outcomes and processes.
This online program is worth 4 hours CPD.
| File type | File name | Number of pages | |
|---|---|---|---|
| Manual - The Use of Mind-Altering Substances (5 MB) | 44 Pages | Available after Purchase |
Michael Mithoefer, MD, clinical assistant professor of psychiatry at the Medical University of South Carolina. In 2009, he completed & published the first FDA approved clinical trial of MDMA assisted psychotherapy for treatment-resistant PTSD, followed by completion of a Phase II trial. He is overseeing a multisite Phase III study of MDMA-assisted psychotherapy in 13 sites around the US (including the Trauma Research Foundation), and another MDMA-assisted psychotherapy multisite study in Europe and Israel.
Speaker Disclosures:
Ismail Lourido Ali, JD, is Director of Policy and Advocacy for the Multidisciplinary Association for Psychedelic Studies (MAPS), a founding board member of the Psychedelic Bar Association, and former Chair of the Board of Directors for Students for Sensible Drug Policy.
Speaker Disclosures:
Financial: Ismail Ali is the policy and advocacy director for Multidisciplinary Association for Psychedelic Studies. He receives a speaking honorarium from PESI, Inc. He has no relevant financial relationships with ineligible organizations.
Non-financial: Ismail Ali works as an activist for compassionate drug policies. He is the founding board member of the Psychedelic Bar Association.
Brian D. Richards, PsyD, completed a master’s degree in Existential-Phenomenological Psychology at Duquesne University, a PsyD at the University of Denver School for Professional Psychology, and a Postdoctoral Fellowship at the Johns Hopkins Behavioral Pharmacology Research Unit, where he contributed to some of the original research administering psilocybin with cancer patients and healthy normal adults. Dr. Richards was formerly a Clinical Director with MedOptions, the largest behavioral health provider in the United States. He also provides Advanced Screenings at Oasis, an acute outpatient center in Maryland, and cares for patients with a cancer diagnosis at Maryland oncology Hematology, The Aquilino Cancer Center. Dr. Richards was a Lead Trainer and Mentor for Compass Pathways (a UK-based Life Sciences Company), and he also mentors students at the California Institute for Integral Studies, the leading Psychedelic Medicine Certificate Program worldwide.
Speaker Disclosures:
Financial: Dr. Brian Richards has employment relationships with the Center for Psychedelic Therapies and Research, Maryland Oncology Hematology, Sunstone Medical, Johns Hopkins University School of Medicine, and the Oasis the Center for Mental Health. He receives a speaking honorarium from PESI, Inc. He has no relevant financial relationships with ineligible organizations.
Non-financial: Dr. Brian Richards has no relevant non-financial relationships.
Gita Vaid, MD, is a board-certified psychiatrist and psychoanalyst and co-founder of the Center for Natural Intelligence, a multidisciplinary laboratory dedicated to psychedelic psychotherapy innovation and clinical practice. A lead instructor at The Ketamine Training Center and a member of the Mount Sinai Psychedelic Psychotherapy Research and Trauma Center, she is a Multidisciplinary Association for Psychedelic Studies-trained psychedelic psychotherapist practicing ketamine-assisted psychotherapy in New York City. Vaid completed her residency training at NYU Medical Center and psychoanalytic training at the Psychoanalytic Association of New York. She trained as a fellow in clinical psychopharmacology and neurophysiology at New York Medical College and completed a research fellowship at NYU Medical Center.
Speaker Disclosures:
Financial: Dr. Gita Vaid maintains a private practice and has employment relationships with the Ketamine Training Center Faculty, New York University, and Mind Medicine Australia. She receives a speaking honorarium from PESI, Inc. She has no relevant financial relationships with ineligible organizations.
Non-financial: Dr. Gita Vaid is a member of the American Psychoanalytic Association and the American Psychiatric Association.
Rachel Yehuda, PhD, Professor of Psychiatry and Neuroscience, is the Director of the Center for Psychedelic Psychotherapy and Trauma Research. She is also Director of the Traumatic Stress Studies Division at the Mount Sinai School of Medicine, which includes the PTSD clinical research program and the Neurochemistry and Neuroendocrinology laboratory the James J. Peters Veterans Affairs Medical Center. Dr. Yehuda is a recognized leader in the field of traumatic stress studies.
She has authored more than 450 published papers, chapters, and books in the field of traumatic stress and the neurobiology of PTSD. Her current interests include the study of risk and resilience factors, psychological and biological predictors of treatment response in PTSD, genetic and epigenetic studies of PTSD and the intergenerational transmission of trauma an PTSD. She has an active federally-funded clinical and research program that welcomes local and international students and clinicians.
Speaker Disclosures:
Financial: Dr. Rachel Yehuda has an employment relationship with the Icahn School of Medicine at Mount Sinai and the Department of Veterans Affairs. She receives a speaking honorarium and recording royalties from PESI, Inc. She has no relevant financial relationships with ineligible organizations.
Non-financial: Dr. Rachel Yehuda is a member of the International Society for Traumatic Stress Studies, the International Society for Neuroscience, and the Anxiety Disorder Association of America. She serves on the scientific advisory board for the National Anxiety Foundation. Dr. Yehuda is an ad hoc grant reviewer for the VA Merit Review Committee, the Department of Defense (DOD), and the National Institute of Mental Health (NIMH).
Rick Doblin, PhD, is the founder and president of the Multidisciplinary Association for Psychedelic Studies (MAPS). His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic therapist. He founded MAPS in 1986, and currently resides in Boston with his wife and dog.
Speaker Disclosures:
Anne Wagner, PhD, CPsych, Adjunct Professor, Department of Psychology & Associate Member, Yeates School of Graduate Studies at Ryerson University, Toronto. Trainer in CBCT and CPT. Team member, MDMA trial for Cognitive Behavioral Conjoint Therapy (CBCT) for PTSD. Founder of Remedy (www.remedycentre.ca), a centre for mental health innovation.
Speaker Disclosures:
Financial: Anne Wagner is the founder of Remedy and Remedy Institute. She has employment relationships with Toronto Metropolitan University, Maya Atlas, and Multidisciplinary Association for Psychedelic Studies Public Benefit Corporation. She receives compensation as a trainer, collaborator, and consultant. She receives grants from Philanthropic Donors and the Australian National Health and Medical Research Council Innovative. Anne Wagner is a consultant with Lykos Therapeutics. She receives a speaking honorarium and recording royalties from PESI, Inc. All relevant financial relationships with ineligible organizations have been mitigated.
Non-financial: Anne Wagner is a member of the Canadian Psychological Association, the International Society of Traumatic Stress Studies, and Association for Behavioral and Cognitive Therapies. She is an Ad hoc reviewer and editor for several peer review journals, for a complete list contact PESI, Inc.
James W. Hopper, PhD, Independent consultant and Instructor in Psychology, Cambridge Health Alliance & Harvard Medical School. Co-editor, Mindfulness-Oriented Interventions for Trauma: Integrating Contemplative Practices. The MDMA Team, Trauma Research Foundation.
Speaker Disclosures:
Financial: James Hopper maintains a private practice and has employment relationships with Harvard University and Cambridge Health Alliance. He receives royalties as a published author. James Hopper receives a speaking honorarium and recording royalties from PESI, Inc. He has no relevant financial relationships with ineligible organizations.
Non-financial: James Hopper serves on the advisory board for Callisto. He is a member of the International Society for Traumatic Stress Studies and the APA Division 56. James Hopper is an Ad hoc reviewer for several peer review journals, for a complete list contact PESI, Inc.
Elizabeth Call, PsyD, offers psychotherapy services to those dealing with life transitions, loss, anxiety, dysthymia, and post-traumatic stress. A psychologist for over 20 years, she utilizes Eye Movement Desensitization and Reprocessing, or EMDR, in her practice as well as Internal Family Systems (IFS) Therapy. Throughout her extensive career, Elizabeth Call, PsyD, has served in multiple capacities in mental health facilities in Massachusetts and Arizona. She is also a former instructor in Harvard Medical School’s Department of Psychiatry.
Speaker Disclosures:
Financial: Dr. Elizabeth Call maintains a private practice, is the co-founder of Burma Border Projects, and has employment relationships with EMDR International Association and EMDR Institute. She is a sub-investigator for FDA phase III trials of MDMA-assisted psychotherapy sponsored by MAPS/MPBC and The Trauma Research Foundation. Dr. Call receives a speaking honorarium and recording royalties from PESI, Inc. She has no relevant financial relationships with ineligible organizations.
Non-financial: Dr. Elizabeth Call is a member of the EMDR International Association and the Massachusetts Psychological Association.
Susan Walker, MD, Instructor in Psychiatry, Harvard Medical School. Child and Adolescent Psychiatrist, Cambridge health Alliance. MDMA Therapy Team Member, the Trauma Research Foundation. Co-principal Investigator, Boston Site of MAPS sponsored MDMA for PTSD study.
Speaker Disclosures:
Financial: Susan Walker is a clinical sub-investigator and therapist with MAPS/MPBC and The Trauma Research Foundation. She receives a speaking honorarium and recording royalties from PESI, Inc. She has no relevant financial relationships with ineligible organizations.
Non-financial: Susan Walker is a member of the American Psychiatric Association and American Psychiatric Association.
Francis Guerriero, MA, LICSW, Private practice, Cambridge, MA; MDMA Therapy team member, The Trauma Research Foundation.
Speaker Disclosures:
Financial: Francis Guerriero maintains a private practice and has an employment relationship with the Trauma Research Foundation. He receives a speaking honorarium and recording royalties from PESI, Inc. He has no relevant financial relationships with ineligible organizations.
Non-financial: Francis Guerriero has a professional relationship as a therapist and sub-investigator under Multidisciplinary Association for Psychedelic Studies (MAPS).
Michael D. Alpert, MD, Staff Psychiatrist, BayCove Mental Health Center, Boston Harvard Medical School; MDMA Therapy team member, the Trauma Research Foundation.
Speaker Disclosures:
Financial: Dr. Michael Alpert maintains a private practice and has employment relationships with Quincy Asian Resources Initiative, Melrose-Wakefield Hospital, and Cambridge Health Alliance. He receives a consulting fee from Lykos Therapeutics and Odyssey PBC. Dr. Alpert receives a speaking honorarium and recording royalties from PESI, Inc. All relevant financial relationships with ineligible organizations have been mitigated.
Non-financial: Dr. Michael Alpert is a member of the American Psychiatric Association and the Massachusetts Medical Society.
Bessel A. van der Kolk, MD, is a clinician, researcher and teacher in the area of post-traumatic stress. His work integrates developmental, neurobiological, psychodynamic and interpersonal aspects of the impact of trauma and its treatment.
Dr. van der Kolk and his various collaborators have published extensively on the impact of trauma on development, such as dissociative problems, borderline personality and self-mutilation, cognitive development, memory, and the psychobiology of trauma. He has published over 150 peer-reviewed scientific articles on such diverse topics as neuroimaging, self-injury, memory, neurofeedback, Developmental Trauma, yoga, theater, and EMDR.
He is founder of the Trauma Center in Brookline, Massachusetts and President of the Trauma Research Foundation, which promotes clinical, scientific, and educational projects.
His 2014 #1 New York Times best seller, The Body Keeps the Score: Brain, Mind, and Body in the Treatment of Trauma, transforms our understanding of traumatic stress, revealing how it literally rearranges the brain’s wiring – specifically areas dedicated to pleasure, engagement, control, and trust. He shows how these areas can be reactivated through innovative treatments including neurofeedback, somatically based therapies, EMDR, psychodrama, play, yoga, and other therapies.
Dr. van der Kolk is the past president of the International Society for Traumatic Stress Studies, and professor of psychiatry at Boston University Medical School. He regularly teaches at conferences, universities, and hospitals around the world.
Speaker Disclosures:
Satisfaction Guarantee
Your satisfaction is our goal and our guarantee. Concerns should be addressed to info@pesi.co.uk or call 01235847393.
Please wait ...